Trial Profile
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Quercetin (Primary)
- Indications Renal failure
- Focus Pharmacodynamics
- 03 Apr 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2025.
- 03 Apr 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2025.
- 14 May 2022 Planned End Date changed from 2 Jun 2022 to 1 Apr 2023.